A Remarkable Case of Thyrotoxicosis Initially Caused by Graves' Disease Followed by a Probable TSHoma - a Case Report

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2020 Aug 29

PMID 32854689

Citations 4

Authors

Mark Quinn

Waiel Bashari

Diarmuid Smith

Mark Gurnell

Amar Agha

Affiliations

Soon will be listed here.

Abstract

Background: Graves' disease is the commonest cause of thyrotoxicosis whilst thyrotropin (TSH)-producing pituitary adenomas (thyrotropinomas, TSHomas) are very rare and account for just 1-2% of all pituitary adenomas. Coexistence of a TSHoma and Graves' disease has been very rarely reported. Here, we report a case of a patient whose initial presentation with primary thyrotoxicosis due to Graves' disease, was subsequently followed by a relapse of thyrotoxicosis due to a probable TSHoma.

Case: A sixty-eight year old woman was referred to our department with classical features of thyrotoxicosis. Initial biochemistry confirmed hyperthyroxinaemia [free thyroxine (fT4) 20.4 pmol/L (reference range 7.0-16.0)] and a suppressed TSH [< 0.02mIU/L (0.50-4.20)]. A technetium pertechnetate uptake scan was consistent with Graves' Disease. She was treated with carbimazole for 18 months and remained clinically and biochemically euthyroid. After stopping carbimazole her fT4 started to rise but TSH remained normal. Laboratory assay interference was excluded. A TRH stimulation test demonstrated a flat TSH response and pituitary MRI revealed a microadenoma. Remaining pituitary hormones were in the normal range other than a slightly raised IGF-1. An C-methionine PET/CT scan coregistered with volumetric MRI (Met-PET-MRI) demonstrated high tracer uptake in the left lateral sella region suggestive of a functioning adenoma. The patient declined surgery and was unable to tolerate cabergoline or octreotide. Thereafter, she has elected to pursue a conservative approach with periodic surveillance.

Conclusion: This is a very unusual case of thyrotoxicosis caused by two different processes occurring in the same patient. It highlights the importance of considering dual pathology when previously concordant thyroid function tests become discordant. It also highlights a potential role of Met-PET-MRI in the localisation of functioning pituitary tumours.

Citing Articles

EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours.

Van Weehaeghe D, Lapauw B, Fraioli F, Cecchin D, Verger A, Guedj E Eur J Nucl Med Mol Imaging. 2024; 51(8):2367-2370.

PMID: 38687371 DOI: 10.1007/s00259-024-06728-4.

Clinical characteristics and outcomes of patients with TSH-secreting pituitary adenoma and Graves' disease - a case report and systematic review.

Khan A, Ibrahim S, Ata F, Wazwaz B, Hanoun M, Belkhair S Thyroid Res. 2024; 17(1):3.

PMID: 38311752 PMC: 10840192. DOI: 10.1186/s13044-023-00184-2.

Central hyperthyroidism combined with Graves' disease: case series and review of the literature.

Mo C, Chen H, Zhang Q, Guo Y, Zhong L Eur Thyroid J. 2023; 12(4).

PMID: 37602950 PMC: 10388650. DOI: 10.1530/ETJ-22-0223.

Double Trouble: A Case Report of Abnormal Uterine Bleeding due to Both Central and Peripheral Pathology.

Lavadi R, Venkatachalaiah R, Prasad M Int J Appl Basic Med Res. 2022; 12(2):134-136.

PMID: 35754675 PMC: 9215186. DOI: 10.4103/ijabmr.ijabmr_500_21.

References

Kirkman M, Jaunmuktane Z, Brandner S, Khan A, Powell M, Baldeweg S . Active and silent thyroid-stimulating hormone-expressing pituitary adenomas: presenting symptoms, treatment, outcomes, and recurrence. World Neurosurg. 2014; 82(6):1224-31. DOI: 10.1016/j.wneu.2014.03.031. View

Vaidya B, Pearce S . Diagnosis and management of thyrotoxicosis. BMJ. 2014; 349:g5128. DOI: 10.1136/bmj.g5128. View

Okuyucu K, Alagoz E, Arslan N, Taslipinar A, Deveci M, Bolu E . Thyrotropinoma with Graves' disease detected by the fusion of indium-111 octreotide scintigraphy and pituitary magnetic resonance imaging. Indian J Nucl Med. 2016; 31(2):141-3. PMC: 4815389. DOI: 10.4103/0972-3919.178322. View

Koulouri O, Steuwe A, Gillett D, Hoole A, Powlson A, Donnelly N . A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome. Eur J Endocrinol. 2015; 173(4):M107-20. DOI: 10.1530/EJE-15-0616. View

Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T . Thyrotropin-producing pituitary adenoma associated with Graves' disease. Eur J Endocrinol. 2004; 151(5):587-94. DOI: 10.1530/eje.0.1510587. View

Vanderpump M . The epidemiology of thyroid disease. Br Med Bull. 2011; 99:39-51. DOI: 10.1093/bmb/ldr030. View

Beck-Peccoz P, Persani L, Mannavola D, Campi I . Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009; 23(5):597-606. DOI: 10.1016/j.beem.2009.05.006. View

Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Kawabe Y, Ishikawa N . Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology. 1996; 137(8):3163-9. DOI: 10.1210/endo.137.8.8754734. View

Kamoun M, dHerbomez M, Lemaire C, Fayard A, Desailloud R, Huglo D . Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and graves' hyperthyroidism. Eur Thyroid J. 2014; 3(1):60-4. PMC: 4005255. DOI: 10.1159/000355386. View

10.

Kageyama K, Ikeda H, Sakihara S, Nigawara T, Terui K, Tsutaya S . A case of thyrotropin-producing pituitary adenoma, accompanied by an increase in anti-thyrotropin receptor antibody after tumor resection. J Endocrinol Invest. 2008; 30(11):957-61. DOI: 10.1007/BF03349244. View

11.

Kamoi K, Mitsuma T, Sato H, Yokoyama M, Washiyama K, Tanaka R . Hyperthyroidism caused by a pituitary thyrotrophin-secreting tumour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves' disease in a middle-aged woman. Acta Endocrinol (Copenh). 1985; 110(3):373-82. DOI: 10.1530/acta.0.1100373. View

12.

Taku N, Koulouri O, Scoffings D, Gurnell M, Burnet N . The use of carbon methionine positron emission tomography (PET) imaging to enhance radiotherapy planning in the treatment of a giant, invasive pituitary adenoma. BJR Case Rep. 2018; 3(2):20160098. PMC: 6159244. DOI: 10.1259/bjrcr.20160098. View

13.

de Carvalho G, Perez C, Ward L . The clinical use of thyroid function tests. Arq Bras Endocrinol Metabol. 2013; 57(3):193-204. DOI: 10.1590/s0004-27302013000300005. View

14.

Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau J . 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2014; 2(2):76-82. PMC: 3821512. DOI: 10.1159/000351007. View

15.

ODonnell J, Hadden D, Weaver J, Montgomery D . Thyrotoxicosis recurring after surgical removal of a thyrotrophin-secreting pituitary tumour. Proc R Soc Med. 1973; 66(5):441-2. PMC: 1644966. View

16.

Lee M, Wang C . Concomitant Graves hyperthyroidism with thyrotrophin-secreting pituitary adenoma. South Med J. 2010; 103(4):347-9. DOI: 10.1097/SMJ.0b013e3181d3ce93. View

17.

Arai N, Inaba M, Ichijyo T, Kagami H, Mine Y . Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report. J Med Case Rep. 2017; 11(1):9. PMC: 5217335. DOI: 10.1186/s13256-016-1172-4. View

18.

Fogelman I, Cooke S, Maisey M . The role of thyroid scanning in hyperthyroidism. Eur J Nucl Med. 1986; 11(10):397-400. DOI: 10.1007/BF00261404. View

19.

Pearce E . Diagnosis and management of thyrotoxicosis. BMJ. 2006; 332(7554):1369-73. PMC: 1476727. DOI: 10.1136/bmj.332.7554.1369. View

20.

Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N . TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev. 2012; 12(2):107-13. DOI: 10.1016/j.autrev.2012.07.003. View